查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941514

生物製药辅料市场规模、份额和趋势分析报告：按产品、材料、剂型、治疗方式、地区和细分市场预测（2026-2033 年）

Biopharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Solubilizes & Surfactants/ Emulsifiers), By Material, By Dosage Form, By Therapeutic Modality, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

生物製药辅料市场概述

2025年全球生物製药辅料市场规模估计为31.8亿美元，预计2033年将达到49.7亿美元。

预计从 2026 年到 2033 年，该行业将以 5.79% 的复合年增长率成长。推动该产业发展的因素包括单株抗体、疫苗、重组蛋白以及基因和细胞疗法等生物製药的快速扩张。

这些复杂的分子需要高品质的辅料来确保药物的稳定性、安全性和有效递送。生物製药研发投入的不断增加以及生物製剂和生物相似药产品线的蓬勃发展，正显着推动市场需求。製剂技术的进步，包括注射、缓释製剂和奈米颗粒製剂等，进一步促进了市场成长。此外，慢性病和罕见病患的疾病上升也促使人们对生物疗法依赖性的增强。严格的产品品质和纯度监管要求也推动了全球生物製药生产中对专用高性能辅料的应用。

生物製药疗法，特别是单株抗体、疫苗、生物相似药以及细胞和基因疗法的快速成长，直接推动了生物製药辅料市场的发展。这些复杂的生物製药本身就存在不稳定性，因此需要先进的稳定剂、缓衝剂和界面活性剂来应对这些问题。蛋白质和病毒载体在生产、储存和给药过程中容易发生聚集、变性和疗效丧失，因此辅料对于维持其构象、溶解度和生物利用度至关重要。随着研发管线的扩展，这种需求也不断成长。每一种新型疗法都需要客製化的配方，而不仅仅是惰性填充剂，例如用于冷冻保护的醣类、用于黏度控制的氨基酸以及用于靶向递送的聚合物，这些都需要辅料来实现生产规模化和临床成功。

核准的激增印证了这一关联。 2024年，FDA核准了约8至9种细胞和基因疗法，其中包括CAR-T产品，例如用于治疗黑色素瘤的lifilucel（Amtagvi）和用于治疗镰状细胞贫血症的Kasgevi。所有这些疗法都需要特殊的赋形剂，以确保载体的稳定性、耐冻融性和递送效率。同样，单株抗体和生物相似药的持续新核准也凸显了对肠外给药和低温运输物流的持续需求，因为这些製剂需要表面活性剂来缓解界面应力，并需要多元醇来确保长期保质期。这些例子表明，从高浓度注射剂到奈米颗粒系统，生物製药的复杂性正在推动赋形剂科学的创新。

生物製药产业在单株抗体、mRNA疫苗、基因疗法和细胞疗法等先进治疗领域的研发投入显着增加，并更重视早期研发阶段的製剂科学。随着生物製药变得日益复杂且依赖递送方式，对能够稳定敏感分子并实现高效标靶递送的专用赋形剂的需求也日益增长。 2025年，西奈山研究人员开发的「更聪明」的mRNA疗法，旨在仅在特定靶细胞中激活，正是这一趋势的典型代表，凸显了该行业向精准mRNA平台的转型。此类创新本质上依赖先进的製剂系统，特别是优化的脂质和聚合物赋形剂，以保护mRNA、控制其释放并确保其被细胞摄取。同时，致力于推进下一代mRNA疫苗和治疗性mRNA计画的生物技术公司正在大力投资于超越新冠疫情期间使用的第一代脂质奈米颗粒的製剂平台。这些研发投资共同加速了针对新兴生物製药模式量身定制的高性能辅料的开发和应用，从而推动了全球市场的成长。

同样，亚什兰公司于2025年6月宣布推出的Viatel生物可吸收聚合物的扩展型产品等创新成果，显示了专用辅料技术如何不断发展，以应对现代生物製药（包括长效注射剂和先进的mRNA疗法）在製剂和递送方面面临的挑战。这项扩展凸显了高效能辅料平台在研发和商业性的日益增长的兴趣，这些平台能够提高稳定性、控制释放并开发新的递送方式，从而推动行业的进一步发展。

目录

第一章调查方法和范围

第二章执行摘要

第三章 生物製药辅料市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 生物製药辅料市场：产品商业分析

  • 按产品分類的市场份额（2025 年和 2033 年）
  • 按产品分類的市场规模、预测和趋势分析（2021-2033 年）
  • 增溶剂、界面活性剂/乳化剂
  • 多元醇
  • 碳水化合物
  • 特殊添加物

第五章 生物製药辅料市场：材料业务分析

  • 按材料分類的市场份额（2025 年和 2033 年）
  • 按材料分類的市场规模、预测和趋势分析（2021-2033 年）
  • 醣类和多元醇
  • 聚合物
  • 胺基酸
  • 无机盐和缓衝剂
  • 特殊共配方添加剂/新型添加剂

第六章：生物製药辅料市场：以剂型分類的商业分析

  • 按剂型分類的市场份额（2025 年和 2033 年）
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 注射液
  • 冷冻干燥製剂
  • 其他的

第七章 生物製药辅料市场：依治疗方式分類的商业分析

  • 按治疗方式分類的市场份额（2025 年和 2033 年）
  • 按治疗方式分類的市场规模、预测和趋势分析（2021-2033 年）
  • 单株抗体
  • 重组蛋白和酶
  • 疫苗
  • 细胞和基因疗法产品
  • 胜肽和寡核苷酸

第八章：生物製药辅料市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Merck KGaA
    • Colorcon
    • BASF SE
    • Associated British Foods plc
    • Signet Excipients Pvt. Ltd（IMCD）
    • Sigachi Industries Limited
    • Spectrum Chemical Manufacturing Corp.
    • Roquette Freres
    • IMCD
    • Clariant
    • DFE Pharma
    • J. RETTENMAIER &SOHNE GmbH+Co KG
    • Evonik Industries AG
Product Code: GVR-3-68038-006-4

Biopharmaceutical Excipients Market Summary

The global biopharmaceutical excipients market size was estimated at USD 3.18 billion in 2025 and is projected to reach USD 4.97 billion by 2033, growing at a CAGR of 5.79% from 2026 to 2033. The industry is growing due to the rapid expansion of biologic drugs such as monoclonal antibodies, vaccines, recombinant proteins, and gene and cell therapies.

These complex molecules require high-quality excipients to ensure stability, safety, and effective drug delivery. Increasing investments in biopharmaceutical research and development, along with a strong pipeline of biologics and biosimilars, are significantly boosting demand. Advances in formulation technologies, including injectable, sustained release, and nanoparticle-based systems, further support market growth. In addition, the rising prevalence of chronic and rare diseases is increasing reliance on biologic therapies. Strict regulatory requirements for product quality and purity are also driving the adoption of specialized, high-performance excipients across global biopharmaceutical manufacturing.

Rapid growth in biopharmaceutical therapeutics, particularly monoclonal antibodies, vaccines, biosimilars, and cell/gene therapies, directly propels the biopharmaceutical excipients market by necessitating advanced stabilizers, buffers, and surfactants to address the inherent instability of these complex biologics. Proteins and viral vectors are prone to aggregation, denaturation, and loss of efficacy during manufacturing, storage, and delivery, making excipients essential for maintaining higher-order structure, solubility, and bioavailability. This demand boost as pipelines expand, with each new therapeutic requiring tailored formulations, such as sugars for cryoprotection, amino acids for viscosity control, and polymers for targeted delivery, that go beyond inert fillers to enable scalable production and clinical success.

The surge in approvals underscores this linkage: in 2024, the FDA greenlit around eight to nine cell and gene therapies, including CAR-T products like lifileucel (Amtagvi) for melanoma and Casgevy for sickle cell disease, each demanding specialized excipients for vector stability, freeze-thaw resilience, and transduction efficiency. Similarly, monoclonal antibodies and biosimilars continue to dominate new approvals, with formulations relying on surfactants to mitigate interfacial stress and polyols to ensure long-term shelf life, thereby amplifying recurring needs in parenteral and cold-chain logistics. These instances highlight how biologic complexity drives innovation in excipient science, from high-concentration injectables to nanoparticle systems.

The biopharmaceutical industry has significantly increased R&D spending on advanced therapeutic classes, including monoclonal antibodies, mRNA vaccines, gene therapies, and cell therapies, with a growing emphasis on formulation science at early development stages. As biologics become more complex and delivery-dependent, demand is increasing for specialized excipients that can stabilize sensitive molecules and facilitate targeted, efficient delivery. In 2025, this trend was characterized by Mount Sinai researchers developing a "smarter" mRNA therapy designed to activate only in specific target cells, highlighting the industry's shift toward precision mRNA platforms. Such innovations inherently rely on advanced formulation systems, particularly optimized lipid and polymer excipients, to protect mRNA, control release, and ensure cellular uptake. Alongside this, biotech companies advancing next-generation mRNA vaccines and therapeutic mRNA programs are investing heavily in formulation platforms that go beyond first-generation lipid nanoparticles used during the COVID-19 era. Collectively, these R&D investments are accelerating the development and adoption of high-performance excipients tailored to emerging biopharmaceutical modalities, thereby driving growth in the global market.

Similarly, innovations such as those in June 2025, Ashland's expanded Viatel bioresorbable polymers demonstrate how specialized excipient technologies are evolving to meet the formulation and delivery challenges posed by modern biologics, including long-acting injectables and advanced mRNA therapies. This expansion highlights the increasing R&D and commercial focus on high-performance excipient platforms that enhance stability, control release, and enable new delivery modalities, thereby further driving growth in the industry.

Global Biopharmaceutical Excipients Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical excipients market report based on product, material, dosage form, therapeutic modality, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Solubilizes & Surfactants/Emulsifiers
    • Triglycerides
    • Esters
    • Others
  • Polyols
    • Mannitol
    • Sorbitol
    • Others
  • Carbohydrates
    • Sucrose
    • Dextrose
    • Starch
    • Others
  • Specialty Excipients
  • Material Outlook (Revenue, USD Million, 2021 - 2033)
  • Sugars & Polyols
  • Polymers
  • Amino Acids
  • Inorganic Salts & Buffers
  • Specialty Co-Processed Excipients / Novel Excipients
  • Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
  • Parenteral (Liquid injectables)
  • Lyophilized (Freeze-dried)
  • Others
  • Therapeutic Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Recombinant Proteins & Enzymes
  • Vaccines
  • Cell & Gene Therapy Formulations
  • Peptides & Oligonucleotides
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Material
    • 1.2.3. Dosage Form
    • 1.2.4. Therapeutic Modality
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Excipients Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Biopharmaceutical Excipients Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Solubilizes & Surfactants/Emulsifiers
    • 4.4.1. Solubilizes & Surfactants/Emulsifiers Market, 2021 - 2033 (USD Million)
    • 4.4.2. Triglycerides
      • 4.4.2.1. Triglycerides Market, 2021 - 2033 (USD Million)
    • 4.4.3. Esters
      • 4.4.3.1. Esters Market, 2021 - 2033 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5. Polyols
    • 4.5.1. Polyols Market, 2021 - 2033 (USD Million)
    • 4.5.2. Mannitol
      • 4.5.2.1. Mannitol Market, 2021 - 2033 (USD Million)
    • 4.5.3. Sorbitol
      • 4.5.3.1. Sorbitol Market, 2021 - 2033 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2021 - 2033 (USD Million)
  • 4.6. Carbohydrates
    • 4.6.1. Carbohydrates Market, 2021 - 2033 (USD Million)
    • 4.6.2. Sucrose
      • 4.6.2.1. Sucrose Market, 2021 - 2033 (USD Million)
    • 4.6.3. Dextrose
      • 4.6.3.1. Dextrose Market, 2021 - 2033 (USD Million)
    • 4.6.4. Starch
      • 4.6.4.1. Starch Market, 2021 - 2033 (USD Million)
    • 4.6.5. Others
      • 4.6.5.1. Others Market, 2021 - 2033 (USD Million)
  • 4.7. Specialty Excipients
    • 4.7.1. Specialty Excipients Market, 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Excipients Market: Material Business Analysis

  • 5.1. Material Market Share, 2025 & 2033
  • 5.2. Material Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Material, 2021 to 2033 (USD Million)
  • 5.4. Sugars & Polyols
    • 5.4.1. Sugars & Polyols Market, 2021 - 2033 (USD Million)
  • 5.5. Polymers
    • 5.5.1. Polymers Market, 2021 - 2033 (USD Million)
  • 5.6. Amino Acids
    • 5.6.1. Amino Acids Market, 2021 - 2033 (USD Million)
  • 5.7. Inorganic Salts & Buffers
    • 5.7.1. Inorganic Salts & Buffers Market, 2021 - 2033 (USD Million)
  • 5.8. Specialty Co-Processed Excipients / Novel Excipients
    • 5.8.1. Specialty Co-Processed Excipients / Novel Excipients Market, 2021 - 2033 (USD Million)

Chapter 6. Biopharmaceutical Excipients Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2025 & 2033
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage form, 2021 to 2033 (USD Million)
  • 6.4. Parenteral (Liquid injectables)
    • 6.4.1. Parenteral (Liquid injectables) Market, 2021 - 2033 (USD Million)
  • 6.5. Lyophilized (Freeze-dried)
    • 6.5.1. Lyophilized (Freeze-dried) Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Biopharmaceutical Excipients Market: Therapeutic Modality Business Analysis

  • 7.1. Therapeutic Modality Market Share, 2025 & 2033
  • 7.2. Therapeutic Modality Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Modality, 2021 to 2033 (USD Million)
  • 7.4. Monoclonal Antibodies
    • 7.4.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Million)
  • 7.5. Recombinant Proteins & Enzymes
    • 7.5.1. Recombinant Proteins & Enzymes Market, 2021 - 2033 (USD Million)
  • 7.6. Vaccines
    • 7.6.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 7.7. Cell & Gene Therapy Formulations
    • 7.7.1. Cell & Gene Therapy Formulations Market, 2021 - 2033 (USD Million)
  • 7.8. Peptides & Oligonucleotides
    • 7.8.1. Peptides & Oligonucleotides Market, 2021 - 2033 (USD Million)

Chapter 8. Biopharmaceutical Excipients Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Biopharmaceutical Excipients Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Material Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Material Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Material Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Material Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Material Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Material Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Material Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Material Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Material Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Material Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Material Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Material Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Material Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Material Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Material Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Material Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Material Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Material Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Material Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Material Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Material Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Material Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Material Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Biopharmaceutical Excipients Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Merck KGaA
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Colorcon
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. BASF SE
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Associated British Foods plc
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Signet Excipients Pvt. Ltd (IMCD)
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Sigachi Industries Limited
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Spectrum Chemical Manufacturing Corp.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Roquette Freres
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. IMCD
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Clariant
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. DFE Pharma
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. J. RETTENMAIER & SOHNE GmbH + Co KG
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Evonik Industries AG
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global biopharmaceutical excipients market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 5 Global biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 6 Global biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 7 Global biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 8 North America biopharmaceutical excipients market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 10 North America biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 11 North America biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 12 North America biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 13 US biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 14 US biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 15 US biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 16 US biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 17 Canada biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 18 Canada biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 19 Canada biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 20 Canada biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 21 Mexico biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 22 Mexico biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 23 Mexico biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 24 Mexico biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 25 Europe biopharmaceutical excipients market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 27 Europe biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 28 Europe biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 29 Europe biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 30 UK biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 31 UK biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 32 UK biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 33 UK biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 34 Germany biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 35 Germany biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 36 Germany biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 37 Germany biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 38 France biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 39 France biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 40 France biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 41 France biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 42 Italy biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 43 Italy biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 44 Italy biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 45 Italy biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 46 Spain biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 47 Spain biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 48 Spain biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 49 Spain biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 50 Norway biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 51 Norway biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 52 Norway biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 53 Norway biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 54 Denmark biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 55 Denmark biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 56 Denmark biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 57 Denmark biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 58 Sweden biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 59 Sweden biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 60 Sweden biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 61 Sweden biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific biopharmaceutical excipients market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific biopharmaceutical excipients market, by product, 2021 - 2033 (USD
  • Table 64 Asia Pacific biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 67 Japan biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 68 Japan biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 69 Japan biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 70 Japan biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 71 China biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 72 China biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 73 China biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 74 China biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 75 India biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 76 India biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 77 India biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 78 India biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 79 Australia biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 80 Australia biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 81 Australia biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 82 Australia biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 83 South Korea biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 84 South Korea biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 85 South Korea biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 86 South Korea biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 87 Thailand biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 88 Thailand biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 89 Thailand biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 90 Thailand biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 91 Latin America biopharmaceutical excipients market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 93 Latin America biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 94 Latin America biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 95 Latin America biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 96 Brazil biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 97 Brazil biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 98 Brazil biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 99 Brazil biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 100 Argentina biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 101 Argentina biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 102 Argentina biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 103 Argentina biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa biopharmaceutical excipients market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 109 South Africa biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 110 South Africa biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 111 South Africa biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 112 South Africa biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 117 UAE biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 118 UAE biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 119 UAE biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 120 UAE biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)
  • Table 121 Kuwait biopharmaceutical excipients market, by product, 2021 - 2033 (USD Million)
  • Table 122 Kuwait biopharmaceutical excipients market, by material, 2021 - 2033 (USD Million)
  • Table 123 Kuwait biopharmaceutical excipients market, by dosage form, 2021 - 2033 (USD Million)
  • Table 124 Kuwait biopharmaceutical excipients market, by therapeutic modality, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical excipients market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Biopharmaceutical excipients market dynamics
  • Fig. 11 Biopharmaceutical excipients market: Porter's five forces analysis
  • Fig. 12 Biopharmaceutical excipients market: PESTLE analysis
  • Fig. 13 Product market, 2021 - 2033 (USD Million)
  • Fig. 14 Solubilizes & Surfactants/Emulsifiers market, 2021 - 2033 (USD Million)
  • Fig. 15 Triglycerides market, 2021 - 2033 (USD Million)
  • Fig. 16 Esters market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 Polyols market, 2021 - 2033 (USD Million)
  • Fig. 19 Mannitol market, 2021 - 2033 (USD Million)
  • Fig. 20 Sorbitol market, 2021 - 2033 (USD Million)
  • Fig. 21 Others market, 2021 - 2033 (USD Million)
  • Fig. 22 Carbohydrates market, 2021 - 2033 (USD Million)
  • Fig. 23 Sucrose market, 2021 - 2033 (USD Million)
  • Fig. 24 Dextrose market, 2021 - 2033 (USD Million)
  • Fig. 25 Starch market, 2021 - 2033 (USD Million)
  • Fig. 26 Others market, 2021 - 2033 (USD Million)
  • Fig. 27 Specialty Excipients market, 2021 - 2033 (USD Million)
  • Fig. 28 Material market, 2021 - 2033 (USD Million)
  • Fig. 29 Sugars & Polyols market, 2021 - 2033 (USD Million)
  • Fig. 30 Polymers market, 2021 - 2033 (USD Million)
  • Fig. 31 Amino Acids market, 2021 - 2033 (USD Million)
  • Fig. 32 Inorganic Salts & Buffers market, 2021 - 2033 (USD Million)
  • Fig. 33 Specialty Co-Processed Excipients / Novel Excipients market, 2021 - 2033 (USD Million)
  • Fig. 34 Dosage Form market, 2021 - 2033 (USD Million)
  • Fig. 35 Parenteral (Liquid injectables) market, 2021 - 2033 (USD Million)
  • Fig. 36 Lyophilized (Freeze-dried) market, 2021 - 2033 (USD Million)
  • Fig. 37 Others market, 2021 - 2033 (USD Million)
  • Fig. 38 Therapeutic Modality market, 2021 - 2033 (USD Million)
  • Fig. 39 Monoclonal Antibodies market, 2021 - 2033 (USD Million)
  • Fig. 40 Recombinant Proteins & Enzymes market, 2021 - 2033 (USD Million)
  • Fig. 41 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 42 Cell & Gene Therapy Formulations market, 2021 - 2033 (USD Million)
  • Fig. 43 Peptides & Oligonucleotides market, 2021 - 2033 (USD Million)
  • Fig. 44 Biopharmaceutical excipients market revenue, by region
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. country dynamics
  • Fig. 48 U.S. Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 49 Canada country dynamics
  • Fig. 50 Canada Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 51 Mexico country dynamics
  • Fig. 52 Mexico Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 53 Europe Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 54 UK country dynamics
  • Fig. 55 UK Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 56 Germany country dynamics
  • Fig. 57 Germany Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 58 France country dynamics
  • Fig. 59 France Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 60 Italy country dynamics
  • Fig. 61 Italy Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 62 Spain country dynamics
  • Fig. 63 Spain Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 64 Norway country dynamics
  • Fig. 65 Norway Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 66 Sweden country dynamics
  • Fig. 67 Sweden Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 68 Denmark country dynamics
  • Fig. 69 Denmark Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 70 Asia Pacific Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 71 Japan country dynamics
  • Fig. 72 Japan Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 73 China country dynamics
  • Fig. 74 China Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 75 India country dynamics
  • Fig. 76 India Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 77 Australia country dynamics
  • Fig. 78 Australia Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 79 South Korea country dynamics
  • Fig. 80 South Korea Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 81 Thailand country dynamics
  • Fig. 82 Thailand Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 83 Latin America Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 84 Brazil country dynamics
  • Fig. 85 Brazil Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 86 Argentina country dynamics
  • Fig. 87 Argentina Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 88 MEA Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 89 South Africa country dynamics
  • Fig. 90 South Africa Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 91 Saudi Arabia country dynamics
  • Fig. 92 Saudi Arabia Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 93 UAE country dynamics
  • Fig. 94 UAE Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 95 Kuwait country dynamics
  • Fig. 96 Kuwait Biopharmaceutical excipients market, 2021 - 2033 (USD Million)
  • Fig. 97 Company categorization
  • Fig. 98 Company market position analysis
  • Fig. 99 Strategic framework